Drug overlaps, shortages may complicate Teva bid for Mylan

NEW YORK (Reuters) - Teva Pharmaceutical Industries' bid for Mylan NV would create a company controlling nearly 25 percent of the U.S. generics market, including drugs in short supply, according to...